• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FTY720与肺肿瘤发展

FTY720 and lung tumor development.

作者信息

Salinas Natália Regina Antunes, Oshima Celina Tizuko Fujiyama, Cury Patrícia Maluf, Cordeiro José Antonio, Bueno Valquiria

机构信息

Division of Immunology, UNIFESP-Federal University of São Paulo, R. Botucatu 862, São Paulo, Brazil.

出版信息

Int Immunopharmacol. 2009 Jun;9(6):689-93. doi: 10.1016/j.intimp.2008.12.007. Epub 2009 Jan 13.

DOI:10.1016/j.intimp.2008.12.007
PMID:19146992
Abstract

FTY720 has been shown to prevent cancer development in experimental models but there is no report whether this beneficial effect is associated with the time point of the drug administration. Lung adenoma was induced in mice by urethane injection followed by different periods of FTY720 administration in order to evaluate lung tumor development. BALB/c mice received urethane intraperitoneally in two doses of 1.5 g/kg and were submitted to five daily doses of FTY720 (1 mg/kg/day) starting just after urethane injection (G2 n=5), 4 weeks after urethane injection (G3 n=10), 8 weeks after urethane injection (G4 n=10) and no FTY720 administration (G1 n=5). Twenty-four weeks after urethane administration mice were evaluated for the number of leukocyte in blood, lymphocytes in spleen, and lungs were evaluated for changes in histology, PCNA and VEGF expression. Lung nodules were present in higher numbers both in non treated (G1; 0.0-7.0) and FTY720 treated 8 weeks after urethane injection (G4; 0.0-6.0). G4 Group also presented the highest number of papillary nodules. G1 and G4 groups presented the lower number of splenocytes and neutrophils. In early time FTY720 treated mice (G2) we observed a slight decrease in PCNA staining and also the lower percentage of VEGF intense staining. Therefore, our data suggest that the benefits of FTY720 treatment are time-dependent and when administered in early periods after lung tumor induction this drug could impair cancer development.

摘要

FTY720已被证明在实验模型中可预防癌症发展,但尚无关于这种有益效果是否与药物给药时间点相关的报道。通过氨基甲酸乙酯注射诱导小鼠肺腺瘤,随后给予不同时间段的FTY720,以评估肺肿瘤的发展。BALB/c小鼠腹腔注射两剂1.5 g/kg的氨基甲酸乙酯,并在氨基甲酸乙酯注射后立即开始接受五剂每日剂量的FTY720(1 mg/kg/天)(G2,n = 5),氨基甲酸乙酯注射后4周(G3,n = 10),氨基甲酸乙酯注射后8周(G4,n = 10),且不给予FTY720(G1,n = 5)。氨基甲酸乙酯给药24周后,评估小鼠血液中的白细胞数量、脾脏中的淋巴细胞数量,并评估肺组织学、PCNA和VEGF表达的变化。未治疗组(G1;0.0 - 7.0)和氨基甲酸乙酯注射8周后接受FTY720治疗组(G4;0.0 - 6.0)的肺结节数量均较多。G4组还呈现出最高数量的乳头状结节。G1组和G4组的脾细胞和中性粒细胞数量较少。在早期接受FTY720治疗的小鼠(G2)中,我们观察到PCNA染色略有下降,VEGF强染色的百分比也较低。因此,我们的数据表明,FTY720治疗的益处具有时间依赖性,并且在肺肿瘤诱导后的早期给药时,这种药物可能会损害癌症发展。

相似文献

1
FTY720 and lung tumor development.FTY720与肺肿瘤发展
Int Immunopharmacol. 2009 Jun;9(6):689-93. doi: 10.1016/j.intimp.2008.12.007. Epub 2009 Jan 13.
2
FTY720 treatment in experimentally urethane-induced lung tumors.FTY720对实验性尿烷诱导的肺肿瘤的治疗作用
J Exp Ther Oncol. 2008;7(1):9-15.
3
Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.在鞘氨醇 1-磷酸激动剂 FTY720 存在的情况下肺肿瘤的发展。
Pathol Oncol Res. 2009 Dec;15(4):549-54. doi: 10.1007/s12253-009-9152-2. Epub 2009 Feb 12.
4
Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice.在诱导期或效应期用FTY720进行治疗可抑制小鼠实验性变应性结膜炎的发展。
Cell Biol Int. 2009 Apr;33(4):534-41. doi: 10.1016/j.cellbi.2009.02.002. Epub 2009 Feb 20.
5
FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.FTY720抑制CD4+CD44高表达CD62L低表达效应记忆T细胞介导的结肠炎。
Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G267-74. doi: 10.1152/ajpgi.00496.2005. Epub 2006 Mar 30.
6
FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination.FTY720治疗可延长完全不相容品系组合中皮肤移植的存活时间。
Transplant Proc. 2004 May;36(4):1015-7. doi: 10.1016/j.transproceed.2004.03.052.
7
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.FTY720:一种有前景的转移性肝细胞癌治疗药物。
Clin Cancer Res. 2005 Dec 1;11(23):8458-66. doi: 10.1158/1078-0432.CCR-05-0447.
8
The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.鞘氨醇-1-磷酸(S1P)受体调节剂FTY720可预防小鼠实验性结肠炎的发生。
Oncol Rep. 2006 Oct;16(4):699-703.
9
Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.新型免疫抑制剂FTY720在小鼠乳腺癌模型中对肿瘤生长和转移有显著预防作用。
Cancer Res. 2002 Mar 1;62(5):1410-9.
10
FTY720 inhibits tumor growth and angiogenesis.FTY720抑制肿瘤生长和血管生成。
Transplant Proc. 2005 Jan-Feb;37(1):110-1. doi: 10.1016/j.transproceed.2004.12.278.

引用本文的文献

1
Small-molecule agents for cancer immunotherapy.用于癌症免疫治疗的小分子药物。
Acta Pharm Sin B. 2024 Mar;14(3):905-952. doi: 10.1016/j.apsb.2023.12.010. Epub 2023 Dec 16.
2
Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer.神经酰胺代谢酶——癌症治疗的靶点
Medicina (Kaunas). 2021 Jul 19;57(7):729. doi: 10.3390/medicina57070729.
3
Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies.多发性硬化症和癌症:疾病修正疗法的阴阳效应。
Front Immunol. 2020 Jan 10;10:2954. doi: 10.3389/fimmu.2019.02954. eCollection 2019.
4
Effect of fingolimod on white blood cell, lymphocyte and neutrophil counts in MS patients.芬戈莫德对多发性硬化症患者白细胞、淋巴细胞及中性粒细胞计数的影响。
Am J Clin Exp Immunol. 2019 Apr 15;8(2):9-15. eCollection 2019.
5
The emerging role of FTY720 (Fingolimod) in cancer treatment.FTY720(芬戈莫德)在癌症治疗中的新作用。
Oncotarget. 2016 Apr 26;7(17):23106-27. doi: 10.18632/oncotarget.7145.
6
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.FTY720 诱导 B16F10-NEX2 小鼠黑色素瘤细胞凋亡,限制体内转移发展,并调节免疫系统。
Clinics (Sao Paulo). 2013 Jul;68(7):1018-27. doi: 10.6061/clinics/2013(07)21.
7
Myeloid-derived suppressor cells and associated events in urethane-induced lung cancer.尿烷诱导肺癌中的髓源性抑制细胞及其相关事件。
Clinics (Sao Paulo). 2013 Jun;68(6):858-64. doi: 10.6061/clinics/2013(06)22.
8
Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.靶向头颈部肿瘤中的鞘脂代谢:合理的治疗潜力。
Expert Opin Ther Targets. 2010 May;14(5):529-39. doi: 10.1517/14728221003752768.
9
S1P metabolism in cancer and other pathological conditions.S1P 代谢在癌症和其他病理状况中的作用。
Biochimie. 2010 Jun;92(6):716-23. doi: 10.1016/j.biochi.2010.02.014. Epub 2010 Feb 16.